Literature DB >> 1370759

The changing role of surgery in metastatic non-seminomatous germ cell tumour.

J Cassidy1, C R Lewis, S B Kaye, D Kirk.   

Abstract

In the last 2 years (1989-1990) we have treated a total of 53 patients with metastatic nonseminomatous germ cell tumours (teratoma). In ten cases surgery to remove residual abdominal masses was required on completion of chemotherapy and normalisation of tumour markers (HCG and AFP). In a further three patients with large intra-abdominal masses and little or no other sites of disease surgery was performed as a therapeutic intervention, in the context of plateauing or rising tumour markers despite intensive chemotherapy. In all three, this approach resulted in a rapid fall in tumour markers, and following further chemotherapy all three remain disease free at 7, 12 and 25 months. For this small sub-group of patient failing to respond to chemotherapy who have resectable lesions, interventional surgery should be considered as part of a combined approach to treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370759      PMCID: PMC1977340          DOI: 10.1038/bjc.1992.24

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients.

Authors:  C J Logothetis; M L Samuels; D E Selig; S Ogden; F Dexeus; D Swanson; D Johnson; A von Eschenbach
Journal:  Am J Med       Date:  1986-08       Impact factor: 4.965

Review 2.  Testicular cancer: the quest continues.

Authors:  P J Loehrer; S D Williams; L H Einhorn
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

3.  BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.

Authors:  C R Lewis; S D Fossà; G Mead; W ten Bokkel Huinink; M J Harding; L Mill; J Paul; W G Jones; C J Rodenburg; B Cantwell
Journal:  Ann Oncol       Date:  1991-03       Impact factor: 32.976

4.  Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma.

Authors:  A van der Gaast; J W Hoekstra; J J Croles; T A Splinter
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

5.  Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction.

Authors:  L H Einhorn; S D Williams; I Mandelbaum; J P Donohue
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

6.  Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.

Authors:  G Pizzocaro; L Piva; R Salvioni; F Zanoni; A Milani
Journal:  Cancer       Date:  1985-11-15       Impact factor: 6.860

7.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

8.  A randomized trial of cytoreductive surgery followed by chemotherapy versus chemotherapy alone in bulky stage testicular cancer with poor prognostic features.

Authors:  N Javadpour; R F Ozols; T Anderson; A B Barlock; R Wesley; R C Young
Journal:  Cancer       Date:  1982-11-15       Impact factor: 6.860

  8 in total
  4 in total

1.  Surgery in metastatic non-seminomatous germ cell tumours.

Authors:  J S Tobias
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

2.  Prognosis after salvage treatment for unselected male patients with germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; R Hartenstein; R Lamerz; W Wilmanns
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

3.  Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.

Authors:  S D Fosså; S P Stenning; A Gerl; A Horwich; P I Clark; P M Wilkinson; W G Jones; M V Williams; R T Oliver; E S Newlands; G M Mead; M H Cullen; S B Kaye; G J Rustin; P A Cook
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

4.  Salvage treatment in male patients with germ cell tumours.

Authors:  D Josefsen; S Ous; J Høie; A E Stenwig; S D Fosså
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.